This PDF is the current document as it appeared on Public Inspection on 03/01/2013 at 08:45 am.
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.Start Printed Page 14100
The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis Panel; Test to Predict Effectiveness of Docetaxel Treatment for Prostate Cancer.
Date: March 28, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, Room-507, 6116 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).
Contact Person: Michael B. Small, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Cancer Institute, NHH, 6116 Executive Blvd., Room 8127, Bethesda, MD 20892-8328, 301-402-0996, email@example.com.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)Start Signature
Dated: February 26, 2013.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-04850 Filed 3-1-13; 8:45 am]
BILLING CODE 4140-01-P